Ticagrelor plus aspirin for 1 month, followed by ticagrelor alone for 23 months compared to 12 months standard DAPT followed by 12 months aspirin alone

to report the clinical 2-year outcome of a combination of ticagrelor and aspirin for 1 month, followed by ticagrelor for 23 months compared to standard DAPT for 12 months (aspirin plus clopidogrel or ticagrelor) followed by another 12 months aspirin alone

randomised, open-label, multicentre superiority trial

patients with stable CAD or ACS

composite of all-cause death or new Qwave MI at 24 months; secondary safety endpoint: bleeding BARC grade 3 to 5